SEIKAGAKU CORPORATION (4548) Stock Price

Biochem Pharmaceutical Industrial Co., Ltd. operates a business focused on the research and development, manufacturing, procurement, and sales of pharmaceuticals and LAL (Limulus Amebocyte Lysate). The company maintains two primary business segments: pharmaceuticals and LAL.

In the pharmaceutical segment, Biochem Pharmaceutical Industrial provides joint function improvement agents, ophthalmic surgical aids, lumbar disc herniation treatments, and submucosal injection materials for endoscopy. The company also manufactures pharmaceutical active ingredients and provides contract manufacturing services for pharmaceuticals.

In the LAL segment, Biochem Pharmaceutical Industrial supplies endotoxin measurement reagents and glucan detection in vitro diagnostic pharmaceuticals. These products play a critical role in ensuring the safety of pharmaceuticals.

The company's subsidiaries include Dalton Chemical Laboratories Inc. and Seikagaku North America Corporation. These subsidiaries handle contract manufacturing of pharmaceuticals and pharmaceutical and medical device development activities in North America.

Additionally, Associates of Cape Cod Inc. conducts research and development, manufacturing, and sales of LAL products, while Associates of Cape Cod International Inc. and Associates of Cape Cod Europe GmbH are responsible for LAL product sales.

Biochem Pharma operates under the motto "Innovation, Integrity, and Dreams with Passion." The company's fundamental policy is to contribute to the health of people worldwide by creating innovative pharmaceuticals that leverage expertise in carbohydrate science. Through this approach, the company aims to achieve sustainable growth and enhance corporate value while fulfilling its social mission.

Under its medium-term management plan (fiscal year ending March 2023 through March 2026), the company targets net sales of 40 billion yen and operating profit of 7 billion yen. To achieve these goals, the company is pursuing U.S. market approval and launch of SI-6603, a lumbar disc herniation treatment, and expanding its pharmaceutical business domestically and internationally. The company has also set research and development expenses at 25% of net sales to strengthen the foundation supporting sustainable growth.

Biochem Pharma has identified five priority initiatives. First, the company aims to obtain regulatory approval and launch SI-6603 in the U.S. market to maximize product value. The company is also accelerating new drug development by leveraging its proprietary drug discovery technology while maintaining and enhancing the business value of its joint function improvement products.

Additionally, the company is building a global production system to strengthen stable supply. The company is expanding its LAL business utilizing genetic recombination technology and promoting development of new diagnostic products. Through these initiatives, the company is strengthening its foundation for achieving sustainable growth.

From a sustainability perspective, the company has identified six material issues and is strengthening its ESG (environmental, social, and governance) initiatives. The company aims to address social challenges and enhance corporate value. The company is also investing in human resource development that supports sustainable growth through improved employee engagement and organizational strengthening.